Andres McAllister
Net worth: 7 139 $ as of 31/08/2026
Net worth: 7 139 $ as of 31/08/2026
Andres McAllister is currently Chief Medical Officer at BioInvent International AB since 2017.
Former positions include Director-Research & Development at Immune Design Corp., Non-Executive Director at Immunexpress Pty Ltd., Principal at Institut Pasteur, Chief Scientific Officer at Debiopharm International SA from 2004 to 2015, Principal at The University of California, San Francisco, and Principal at Centre d'Immunologie Pierre Fabre.
Education includes doctorates from Université Paris 1 Panthéon-Sorbonne and Universidad del Rosario.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 31/12/2025 | 3,009 ( 0% ) | 7 139 $ | 31/08/2026 |
| Companies | Position | Start |
|---|---|---|
| BIOINVENT INTERNATIONAL AB | Chief Tech/Sci/R&D Officer | 01/01/2017 |
| Companies | Position | End |
|---|---|---|
Debiopharm International SA
Debiopharm International SA BiotechnologyHealth Technology Operates as a biopharmaceutical company which develops drugs to cure cancer and infectious diseases | Chief Tech/Sci/R&D Officer | 01/09/2015 |
Immunexpress Pty Ltd.
Immunexpress Pty Ltd. Medical SpecialtiesHealth Technology Engages in creating molecular diagnostics for sepsis | Director/Board Member | - |
Centre d'Immunologie Pierre Fabre | Corporate Officer/Principal | - |
Institut Pasteur
Institut Pasteur Investment Trusts/Mutual FundsMiscellaneous Functions as a foundation or endowment | Corporate Officer/Principal | - |
The University of California, San Francisco
The University of California, San Francisco Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | - |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 9 |
|---|---|
BioInvent International AB
BioInvent International AB BiotechnologyHealth Technology Develops and manufactures immunomodulatory antibodies for cancer treatment | Health Technology |
Institut Pasteur
Institut Pasteur Investment Trusts/Mutual FundsMiscellaneous Functions as a foundation or endowment | Miscellaneous |
Debiopharm International SA
Debiopharm International SA BiotechnologyHealth Technology Operates as a biopharmaceutical company which develops drugs to cure cancer and infectious diseases | Health Technology |
The University of California, San Francisco
The University of California, San Francisco Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Université Paris 1 Panthéon-Sorbonne
Université Paris 1 Panthéon-Sorbonne Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Immune Design Corp.
Immune Design Corp. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical and clinical-stage immunotherapy company | Health Technology |
Immunexpress Pty Ltd.
Immunexpress Pty Ltd. Medical SpecialtiesHealth Technology Engages in creating molecular diagnostics for sepsis | Health Technology |
Universidad del Rosario
Universidad del Rosario Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Centre d'Immunologie Pierre Fabre |
Select your edition
All financial news and data tailored to specific country editions